Drug Discovery Technologies Market Report 2026

The drug discovery technologies market size has grown rapidly in recent years. It will grow from $80.76 billion in 2025 to $90.23 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to screening automation development, genomic research expansion, computational chemistry adoption, biologics research growth, drug pipeline complexity.

The drug discovery technologies market size is expected to see rapid growth in the next few years. It will grow to $138.44 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to ai-driven molecular design, personalized medicine focus, advanced analytics integration, novel therapeutic modalities, accelerated discovery timelines. Major trends in the forecast period include growing adoption of high throughput screening, increased use of bioinformatics platforms, expansion of rna-based drug discovery, rising application of nanotechnology in drug design, integration of pharmacogenomics in discovery.

The increasing healthcare expenditures are expected to drive the growth of the drug discovery technologies market in the coming years. Healthcare expenditures encompass all financial resources dedicated to medical services, public health programs, family planning, nutrition initiatives, and emergency health support. Spending continues to rise due to growing demand for advanced treatments, aging populations, the burden of chronic diseases, and expanded access to healthcare services. The drug discovery technologies market benefits from this trend by utilizing increased funding to enhance research platforms, analytical tools, and digital technologies that accelerate the development of new therapies. For instance, in May 2024, according to the Office of National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms between 2022 and 2023, compared with a 0.9% increase in 2022. Therefore, the rise in healthcare expenditures is supporting the growth of the drug discovery technologies market.

Major companies in the drug discovery technologies market are focusing on developing advanced solutions such as integrated drug research and development platforms to improve precision, enable high-throughput analysis, and accelerate the discovery of new therapeutic compounds. A drug R&D platform is a unified framework that streamlines the processes of identifying, designing, optimizing, and validating pharmaceutical candidates through cohesive workflows and data-driven tools. For example, in July 2023, Dotmatics Inc., a US-based scientific software company, launched the Small Molecule Drug Discovery Solution, a comprehensive R&D platform featuring pre-configured workflows and advanced data management capabilities designed to foster collaboration, increase productivity, and streamline operations. This platform allows researchers to efficiently convert data into actionable insights and supports a seamless workflow from hit discovery to lead optimization, accelerating the development of life-enhancing drug therapies.

In June 2024, Simulations Plus Inc., a US-based software company, acquired Pro-ficiency Holdings Inc. for $100 million. Through this acquisition, Simulations Plus aims to expand its drug discovery and development capabilities by integrating simulation-based learning, intelligence, and compliance solutions to enhance clinical trial operations, commercialization, and data analytics. Pro-ficiency Holdings Inc. is a US-based company that provides simulation-based learning and compliance solutions for the life sciences industry, including drug discovery technologies.

Major companies operating in the drug discovery technologies market are F. Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc., Merck KGaA, GE HealthCare Technologies Inc., Agilent Technologies Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Evotec SE, Curia Global Inc., Aragen Life Sciences Private Limited, Luminex Corporation, BioXcel Therapeutics Inc., Certara Inc., Schrödinger Inc., Sygnature Discovery Ltd., Recursion Pharmaceuticals Inc., InSilico Medicine Inc., ChemAxon Ltd., Enamine Ltd., BenevolentAI Limited, OpenEye Scientific Software Inc., Collaborative Drug Discovery Inc., Pharmacelera S.L., Gyros Protein Technologies AB, Optibrium Ltd., Cresset Group, Relay Therapeutics Inc.

North America was the largest region in the drug discovery technologies market in 2025. The regions covered in the drug discovery technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug discovery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the drug discovery technologies market by increasing costs of imported screening systems, bioanalytical instruments, and software platforms. Pharmaceutical and biotech firms in developed regions are most affected. These tariffs increase technology acquisition and maintenance costs, slowing adoption of advanced discovery platforms and limiting access for smaller research organizations. However, they encourage local manufacturing of research instruments and innovation in cost-efficient discovery technologies, supporting the development of regionally produced platforms and alternative solutions that lower long-term dependency on imported systems.

The drug discovery technologies market research report is one of a series of new reports that provides drug discovery technologies market statistics, including drug discovery technologies industry global market size, regional shares, competitors with a drug discovery technologies market share, detailed drug discovery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery technologies industry. This drug discovery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug discovery technology refers to the range of techniques and strategies used to discover new drugs and identify chemical entities with potential as medicines and therapeutic agents. These technologies focus on identifying and developing potential drug candidates for the treatment of various diseases.

The main types of drug discovery technologies include high-throughput screening, genomics, nanotechnology, bioinformatics, combinatorial chemistry, pharmacogenomics, biochips, bioanalytical instruments, and ribonucleic acid interference (RNAi). High-throughput screening is a method for rapidly assessing the biological activity of tens of thousands to millions of samples, helping to accelerate drug discovery. These technologies are applied in the development of small molecule drugs and biologic drugs and are used in addressing diseases such as cancer, immunological disorders, neurological diseases, cardiovascular diseases, and others. End users include pharmaceutical companies, biopharmaceutical companies, biotechnology firms, research institutes, and more.

The drug discovery technologies market consists of revenues earned by entities by drug screening, predictive analytics, modeling, simulation, and computational capabilities. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug discovery technologies market also includes sales of automation tools, computational chemistry software, imaging software, and mass spectrometers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.